Response to: Tocilizumab, neuromyelitis optica (NMO), and multiple sclerosis

Mult Scler. 2016 Dec;22(14):1892-1893. doi: 10.1177/1352458516643398. Epub 2016 Apr 11.

Authors

Philippe Beauchemin^{1

2}, Robert Carruthers²

Affiliations

¹ Hôpital de l'Enfant-Jésus, CHU de Québec, Département des sciences neurologiques, Université Laval, Québec City, QC, Canada philippe.beauchemin.1@ulaval.ca.
² UBC Hospital MS Clinic, Department of Neurology, University of British Columbia (UBC), Vancouver, BC, Canada.

PMID: 27068553
DOI: 10.1177/1352458516643398

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Autoantibodies
Humans
Multiple Sclerosis*
Neuromyelitis Optica*

Substances

Antibodies, Monoclonal, Humanized
Autoantibodies
tocilizumab